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Vorinostat positively regulates synaptic plasticity
genes expression and spine density in HIV
infected neurons: role of nicotine in progression
of HIV-associated neurocognitive disorder
Venkata Subba Rao Atluri1, Sudheesh Pilakka-Kanthikeel1, Thangavel Samikkannu1, Vidya Sagar1,
Kesava Rao Venkata Kurapati1, Shailendra K Saxena2, Adriana Yndart1, Andrea Raymond1, Hong Ding1,
Oscar Hernandez1 and Madhavan PN Nair1*

Abstract
Background: HIV-associated neurocognitive disorder (HAND) is characterized by development of cognitive,
behavioral and motor abnormalities, and occurs in approximately 50% of HIV infected individuals. In the United
States, the prevalence of cigarette smoking ranges from 35-70% in HIV-infected individuals compared to 20% in general
population. Cognitive impairment in heavy cigarette smokers has been well reported. However, the synergistic effects
of nicotine and HIV infection and the underlying mechanisms in the development of HAND are unknown.
Results: In this study, we explored the role of nicotine in the progression of HAND using SK-N-MC, a neuronal cell
line. SK-N-MC cells were infected with HIV-1 in the presence or absence of nicotine for 7 days. We observed significant
increase in HIV infectivity in SK-N-MC treated with nicotine compared to untreated HIV-infected neuronal cells. HIV and
nicotine synergize to significantly dysregulate the expression of synaptic plasticity genes and spine density; with a
concomitant increase of HDAC2 levels in SK-N-MC cells. In addition, inhibition of HDAC2 up-regulation with the
use of vorinostat resulted in HIV latency breakdown and recovery of synaptic plasticity genes expression and spine
density in nicotine/HIV alone and in co-treated SK-N-MC cells. Furthermore, increased eIF2 alpha phosphorylation,
which negatively regulates eukaryotic translational process, was observed in HIV alone and in co-treatment with
nicotine compared to untreated control and nicotine alone treated SK-N-MC cells.
Conclusions: These results suggest that nicotine and HIV synergize to negatively regulate the synaptic plasticity gene
expression and spine density and this may contribute to the increased risk of HAND in HIV infected smokers. Apart
from disrupting latency, vorinostat may be a useful therapeutic to inhibit the negative regulatory effects on synaptic
plasticity in HIV infected nicotine abusers.
Keywords: Human synaptic plasticity, PCR array, Spine density, HIV, Nicotine, HDAC2, eIF2α, Vorinostat, SK-N-MC
neuronal cells, Neurocognitive disorder
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Background
HIV-1 infection, cigarette smoking and drug abuse are
global public health concerns. Several studies report that
nicotine, the psychoactive drug in tobacco products that
induces dependence among smokers, is one of the major
immunomodulatory agents [1-5]. Nicotine dependence
is the most common form of chemical dependence in
the United States. Research suggests that nicotine may
be as addictive as heroin, cocaine and alcohol [3,5]. In
the United States, the prevalence of cigarette smoking
ranges from 35-70% in HIV-infected individuals compared to approximately 20% in general population [6-9].
Infection with HIV is often associated with a wide
range of neurological and neuropathological abnormalities, which are collectively known as HIV- associated
neurocognitive disorder (HAND). HAND is characterized by development of cognitive, behavioral and motor
abnormalities, and occurs in approximately 50% of HIV
infected individuals [10,11]. Previous studies indicate
that HIV-1 clade B (predominant subtype found in the
United States and in the western world) being more
neuropathogenic than clade C (predominant in subSaharan Africa and Asia) [12-14]. Experimental evidence
and clinical observations suggest a correlation between
smoking and increased risk for neurological disorders
[15]. A great deal of research has focused on the pathophysiological and clinical effects of nicotine. In human
studies, nicotine and other agonists of the nicotinic
acetylcholine receptor (nAChRs) have been reported to
improve cognitive performance in healthy adults and in
different psychiatric populations [16,17]. In studies with
rodents, the results have been mixed with observations
of improvement, impairment, or no effect on various
measures of learning and memory following acute or
chronic systemic treatment [16]. However, the effect of
nicotine on HIV-1 pathogenesis has received limited research attention. Few studies have reported that nicotine
exacerbates HIV-1 replication in in vitro-infected alveolar macrophages and primary human microglia [18,19].
Further, limited examination of the neuropathogenic effects of nicotine on HIV-1 infection of CNS cells has
shown that galantamine and nicotine exert synergistic
effect on the inhibition of microglial cell activation induced by HIV-1 gp120 [20]. A recent study reported that
exposure to tobacco smoke extract increases the blood–
brain barrier permeability and plays a critical role in
pathophysiology of ischemia [21].
Although few studies have reported deficits in learning, memory, and global cognitive performance among
cigarette smokers living with HIV [22,23], the underlying mechanisms associated with the use of nicotine
and the development of HAND in these patients are unknown. New memory formation involves gene expressiondependent changes in synaptic structure and plasticity in
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the hippocampus [24]. Recently, we have reported dysregulated synaptic plasticity genes expression and decreased
spine density in HIV infected CNS cells [13]. Although
epigenetic modifications are known to regulate gene expression during HIV infection [25], molecular and biochemical evidence on epigenetic mechanisms in CNS cells
in response to HIV and nicotine are lacking. Acetylation
and deacetylation of histone proteins associated with
chromatin plays a pivotal role in the epigenetic regulation
of transcription and other functions in cells, including
neurons.
HDACs often function as a component of the transcriptional repressor complex to silence gene expression and
induce chromatin compaction through histone protein
deacetylation. HDAC2 functions in modulating synaptic
plasticity and long-lasting changes of neural circuits,
which in turn negatively regulates learning and memory
[26]. HDAC inhibitors are emerging as an exciting new
class of potential therapeutic agents for the treatment of
solid and hematological malignancies. Vorinostat also
known as suberanilohydroxamic acid (SAHA) was the first
histone deacetylase inhibitor approved by the U.S. Food
and Drug Administration for the treatment of Cutaneous
T-Cell Lymphoma. Vorinostat binds to the catalytic domain of the histone deacetylases (HDACs). This allows
the hydroxamic moiety to chelate zinc ion located in the
catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Vorinostat was
also shown to cross the blood–brain barrier in a mouse
model of Huntington's disease [27]. Therefore, use of
vorinostat as a therapeutic agent in the CNS related
diseases may be useful. In the down-stream, translation
of eukaryotic mRNAs is regulated primarily at the level
of initiation. Two main mechanisms by which translation is controlled are the formation of the ternary complex via eIF2 and the recruitment of the ribosome to
the mRNA via 4E-BPs. Phosphorylation of an α subunit
of eIF2 (at Ser51) converts the protein from a substrate
to a competitive inhibitor of the GDP/GTP-exchange
reaction by decreasing the rate of dissociation of eIF2
from eIF2B [28,29]. This causes a decrease in general
translational initiation [29,30]. We hypothesize that by
inducing the transcriptional repression, HDAC2 plays a
major role in the neuropathogenesis caused by HIV and
nicotine (Figure 1). In the down-stream, we hypothesize
that translational process in HIV infected cells will be
affected by eIF2α phosphorylation (Figure 2).
In the current study, we have analyzed the effect of
nicotine on the differential expression of synaptic plasticity genes, spine density in an in vitro HIV infection
model using neuronal cells. Along with the dysregulated
synaptic plasticity genes and altered spine density, we have
found increased levels of HDAC2 expression indicating
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Figure 1 (See legend on next page.)
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(See figure on previous page.)
Figure 1 A hypothetical model for the role of HDAC2 in transcriptional repression of synaptic plasticity genes in neuronal cells
infected with HIV and/or in the presence of nicotine. During the gene transcription, the DNA to be transcribed is associated with histone
proteins (blue) that are modified by the addition of acetyl groups (green). This modification results in a relaxed chromatin configuration that
allows the transcriptional machinery access to the DNA. Up-regulation of HDAC2 during HIV infection and/or nicotine treatment leads to deletion
of acetyl groups from histone proteins, resulting in a condensed chromatin that limits the binding of the transcriptional machinery, thereby
decreasing gene transcription. Thus, inhibition of HDAC2 by using vorinostat may block these enzymatic processes and return the chromatin to a
relaxed state, allowing gene transcription.

the transcriptional repression of synaptic plasticity genes
in these cells. We also found increased eIF2α subunit
phosphorylation (at Ser51) which may associate with the
translational repression of synaptic plasticity genes in HIV
alone infected SK-N-MC cells and in the presence of nicotine. These negative regulatory effects of HIV infection
and nicotine on the expression of synaptic plasticity genes
and spine density were reversed by the HDAC inhibitor
vorinostat. This study suggests that nicotine synergistically
acts with HIV to down-regulate synaptic plasticity genes
and alter spine density, potentially via upregulation of
HDAC2. The use of vorinostat may help to reverse these
negative regulatory effects (induced by HDAC2) on synaptic plasticity genes expression and spine density.

Results
Increased HIV-infectivity rate of neuronal cells in the
presence of nicotine

We observed significant increase in HIV-infection in
nicotine-treated HIV-infected SK-N-MC compared to
the HIV- infected alone cells by using the LTR real-time
PCR. We also observed significantly increased HIV infection (latency disruption) in HIV infected neuronal
cells in the presence of vorinostat by both LTR real-time
PCR (Figure 3) and p24 ELISA (data not shown). We
did not see significant levels of vorinostat induced latency disruption in HIV infected neuronal cells in the
presence of nicotine and vorinostat.
Differential expression of human synaptic plasticity genes
in SK-N-MC cells infected with HIV and/or in the presence
of nicotine

Figure 2 A hypothetical model for the role of eIF2α
phosphorylation in translational repression of synaptic
plasticity genes in HIV infected neuronal cells. In HIV infection,
due to partial phosphorylation of eIF2α, general translation is reduced
and ATF4 mRNA translation is augmented. As a consequence, the
expression of synaptic plasticity and memory-related genes is blocked.

Out of 84 human synaptic plasticity genes expression
analyzed by human synaptic plasticity PCR array, 23 synaptic plasticity genes were significantly down-regulated
whereas 16 synaptic plasticity genes were significantly
up-regulated in nicotine treated SK-N-MC cells. In the
HIV infected SK-N-MC cells, while 28 synaptic plasticity
genes were down-regulated, 8 synaptic plasticity genes
were significantly up-regulated. However, in the presence
of nicotine, in HIV infected SK-N-MC cells, a total of 47
genes were significantly down-regulated (3–22 fold) and
4 genes were significantly up-regulated (Table 1). Out of
the total 84 genes, 21 genes were commonly down regulated in all the three groups (nicotine treated, HIV
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nicotine to the expression levels approximately equal to
the control cells (Figures 5 and 6).
Vorinostat positively regulates synaptic plasticity genes
expression in HIV infected and/or nicotine treated
neuronal cells

Figure 3 Increased HIV-infectivity rate of neuronal cells in the
presence of nicotine. SK-N-MC cells were infected with HIV for 7 days
with/without nicotine. Cells were harvested; RNA was isolated from the
infected cells. LTR real-time PCR analysis indicated that HIV infectivity
rate was significantly higher in the presence of nicotine than HIV alone
infected cells. Significantly increased HIV infectivity (latency disruption)
in vorinostat treated neuronal cells was also observed (not significant
in combination with nicotine). (*, p ≤ 0.05; NS-Not Significant).

infected and HIV along with nicotine). Figure 4 (Venn
diagram) shows the number of down-regulated synaptic
plasticity genes in SK-N-MC neuronal cells infected with
HIV and/or nicotine combination. These results indicate
that in the presence of nicotine, dysregulation of synaptic plasticity genes will be further increased in HIV infected neuronal cells.
Vorinostat regulates HDAC2 expression in neuronal cells
infected with HIV and/or treated with nicotine

Using qPCR (Figure 5) and western blot analysis (Figure 6),
we observed significantly higher HDAC2 levels in nicotine
treated cells, HIV infected cells and HIV infected cells
treated with nicotine compared to control cells, indicating
possible epigenetic changes which are responsible for the
transcriptional repression of synaptic plasticity genes. But
we did not see additive/synergistic effect on HDAC2 expression in HIV infected cells in the presence of nicotine.
Vorinostat is a potent inhibitor of Classes I and II histone
deacetylases. To inhibit the up-regulation of HDAC2 expression in SK-N-MC cells infected with HIV and/or
treated with nicotine, these test groups were treated with
vorinostat on the 5th day of infection and/or nicotine
treatment. Using vorinostat (at 1 μM conc.), we were able
to inhibit the HDAC2 expression levels in the nicotine
treated cells and HIV infected neuronal cells with/without

In vorinostat alone treated SK-N-MC cells, total 19 synaptic plasticity genes were significantly up-regulated
while only 4 genes were significantly down-regulated. 24
synaptic plasticity genes out of 28 genes, which were
down-regulated with HIV infection, were recovered and
16 more genes were significantly up-regulated in the
presence of vorinostat. Further, in the case of HIV infected
cells treated with nicotine, out of 47 down-regulated
genes, expression of 40 genes were recovered upon vorinostat treatment and 15 more genes were up-regulated.
Surprisingly, four genes down-regulated (CREM, NFKB1,
RHEB, TIMP1) in the presence of vorinostat alone were
consistently down-regulated in all the groups containing
vorinostat. Excluding these four genes, vorinostat failed to
recover the expression of EGR4, HOMER1 and TNF in
HIV infected cells in the presence of nicotine (Table 1 and
Figure 7). These results indicate that vorinostat can inhibit
the negative regulatory effects on synaptic plasticity genes
expression (mediated by increased HDAC2 expression) in
HIV infected cells in the presence of nicotine.
Synergistic decrease of spine density in HIV infected
neuronal cells in the presence of Nicotine

Using the established protocol, we have observed for
change in spine density in HIV infected SK-N-MC cells
and/or nicotine/vorinostat combination in comparison
to the control cells [13]. In nicotine alone treated cells,
spine density was significantly less than the control cells.
In HIV only infected cells, spine density was significantly
less than the nicotine treated cells (p < 0.02). Interestingly, HIV infected cells in the presence of nicotine exhibit decreased spine density compared to nicotine/HIV
alone infected cells. Spine density was recovered when
these nicotine/HIV/HIV + nicotine infected cells were
treated with the vorinostat (Figure 8).
eIF2α phosphorylation in SK-N-MC cells infected with HIV
and/or treated with nicotine

Phosphorylation of the α-subunit of eukaryotic initiation
factor 2 (eIF2α) inhibits the initiation of translational
process. To investigate whether the translational process
is affected or not in the HIV infected and/or nicotine
treated neuronal cells, eIF2α phosphorylation (at Ser51)
was analyzed. In the SK-N-MC cells, significant eIF2α
phosphorylation (at Ser51) was observed in HIV infected
cells alone and in combined treatment with nicotine.
We did not observe significant eIF2α phosphorylation in
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Table 1 Human synaptic plasticity genes expression in HIV infected neuronal cells and in combination with nicotine
and/or vorinostat (fold change)
Genes

Vorinostat

HIV

HIV + Vorinostat

Nicotine

Nicotine + Vorinostat

HIV + Nocotine

ADAM105,6,9

1.47

1.89

1.24

4.12

1.45

−1.03

1.11

ADCY13

1.12

−3.39

1.12

−3.15

2.26

−3.99

1.17

ADCY83

1.12

−3.39

1.12

−3.15

2.26

−3.99

−1.96

AKT17

3.10

2.96

3.84

3.42

4.59

−1.32

4.23

1,9

ARC

−1.09

1.30

1.54

1.07

2.79

−4.81

1.55

BDNF1,3

1.12

−3.39

1.12

−3.15

2.26

−3.99

−1.96

CAMK2A3

1.12

−3.39

1.12

−3.15

2.26

−3.99

−1.96

CAMK2G3,7

1.48

1.11

1.46

1.16

1.62

−3.38

1.33

CDH2

1.12

−3.06

1.12

−3.15

2.26

−3.99

−1.37

CEBPB1

1.37

2.50

1.64

1.98

2.07

−3.07

2.04

1

CEBPD

1.39

1.89

1.96

1.35

3.03

−3.07

1.96

CNR13

1.12

−3.39

1.12

−3.15

2.26

−3.99

−1.96

CREM1

−35.90

−9.78

−15.78

−8.26

−16.02

−25.41

−16.77

EGR11

2.37

1.13

1.34

−5.68

1.15

−9.24

1.20

1

EGR2

6.89

1.94

4.29

9.22

3.34

1.43

2.43

EGR31

1.86

1.01

3.89

−1.76

2.94

−3.99

2.43

EGR4

−1.95

−6.69

−1.96

−3.20

1.03

−8.74

−4.28

EPHB28

1.71

−2.97

1.74

−3.15

2.36

−3.99

1.43

3,5

1

HIV + Nicotine + Vorinostat

FOS

1.15

−1.24

1.07

1.07

1.43

−3.83

−1.12

GABRA53,8

1.91

−3.39

1.12

−1.62

2.26

−3.99

−1.96

GRIA1

1.12

−3.39

1.12

−3.15

2.26

−3.99

−1.96

GRIA23,4,8

4.04

2.38

2.55

2.09

4.40

1.10

3.49

GRIA4

12.85

9.24

4.35

2.39

5.73

−1.50

3.12

GRIN13,7,8,9

31.65

5.89

28.25

4.70

39.89

−1.02

35.80

GRIN2A3,5,7,8,9

2.26

−3.06

1.12

−2.14

2.26

−3.99

−1.07

GRIN2B3,5,7,8,9

2.26

−3.39

1.12

−3.15

2.26

−3.99

−1.07

GRIN2C

2.26

−1.73

1.80

−3.15

2.26

−3.99

−1.07

GRIN2D3,7,8

4.25

1.42

2.17

4.97

4.25

−1.34

2.80

1

3,4,8,9

4,8,9

3,7,8,9

GRIP1

3.07

−1.09

2.36

2.72

3.07

−1.90

1.96

GRM14,8,9

1.12

−3.39

1.12

−3.15

2.26

−3.99

−1.96

GRM24,8

1.85

1.93

1.12

3.79

2.26

−1.47

1.01

GRM38,9

1.12

−3.39

1.12

−2.11

2.26

−3.99

−1.96

GRM48

2.26

−3.06

1.12

1.34

2.26

−3.99

−1.21

GRM58

1.12

3.38

1.12

−1.15

2.26

−2.75

−1.96

GRM78

1.12

−3.06

1.12

2.45

2.26

−2.33

−1.10

HOMER11,9

−1.64

−1.13

−2.95

1.30

−2.68

−1.93

−3.13

4

IGF14

1.96

9.13

1.32

11.75

1.19

3.37

1.17

INHBA2

4.15

−2.11

2.03

−1.43

2.22

−5.89

2.25

JUN

8.84

−1.39

6.73

−1.65

8.04

−11.61

6.33

JUNB1

3.93

2.73

4.06

1.42

10.84

−3.97

3.79

1

KIF1710

2.30

−2.99

3.20

−1.89

4.19

−9.30

3.34

MMP91,3,6

3.06

−2.68

2.00

−2.94

2.99

−10.32

1.62

1.17

−4.59

1.41

−6.80

1.40

−39.88

1.25

5

NCAM1
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Table 1 Human synaptic plasticity genes expression in HIV infected neuronal cells and in combination with nicotine
and/or vorinostat (fold change) (Continued)
NFKB11
1

−20.48

−6.41

−35.26

−5.45

−26.76

−25.59

−48.77

NFKBIB

9.61

12.91

13.09

14.56

14.20

13.54

13.66

NGF1,4

5.79

1.45

4.92

1.30

4.72

−3.01

6.55

4

NGFR

1.30

2.50

1.13

2.65

1.37

−2.18

1.04

NOS14

1.12

−3.39

1.12

1.22

2.26

−3.99

−1.96

NPTX21

1.12

2.22

1.12

1.28

2.26

−3.29

3.19

NR4A11

5.11

1.47

6.73

2.54

4.82

−1.79

4.67

NTF31

1.12

−3.06

1.12

1.92

2.26

−1.53

−1.96

NTF43

1.98

1.14

4.82

−1.30

5.85

−6.14

4.63

NTRK2

1.12

−3.40

1.12

−3.15

2.26

−3.99

−1.96

PCDH81,5

2.37

2.53

1.29

3.37

2.04

−1.68

1.35

3

PICK1

1.58

1.54

2.64

1.18

2.65

−4.21

2.30

PIM11

11.19

4.86

25.46

10.59

33.08

2.55

32.95

PLAT1,4,6

−1.03

−1.82

−1.03

−2.34

1.97

−4.59

−2.25

PLCG13

2.19

1.23

2.35

1.39

3.78

−3.62

2.91

4,9

PPP1CA

−2.04

1.54

1.37

−1.69

1.16

−13.25

1.48

PPP1R14A4

1.12

−3.06

1.12

−3.15

2.26

−3.99

−1.96

PPP2CA4

6.52

10.06

6.87

13.31

7.20

3.28

6.64

PRKCA3,4

5.40

2.80

3.29

7.23

4.43

2.24

2.93

3

PRKCG

2.30

−5.07

2.16

−4.84

3.22

−6.62

2.12

PRKG14

1.12

−3.06

1.12

−3.15

2.26

−3.99

−1.47

RAB3A3

86.46

56.49

106.15

75.27

91.65

15.81

103.39

1.30

2.00

1.34

3.26

1.45

−1.12

1.25

RELN

1.12

−3.06

1.12

−3.15

2.26

−3.99

−1.96

RGS21

5.29

−1.40

2.62

−1.12

4.46

−2.90

2.38

−49.73

−32.90

−57.68

−35.16

−46.92

−84.30

−69.94

2.29

2.58

1.91

4.70

1.89

1.52

1.28

3,4,7

RELA1
5,6

1

RHEB

SIRT110
1

2.70

2.83

1.82

3.19

2.33

−1.44

1.60

TIMP16

−18.20

−38.00

−20.11

−24.02

−15.69

−79.20

−17.73

TNF1,5

−2.65

−5.47

−2.28

−2.63

−1.42

−5.97

−9.30

SRF

Out of 84 genes analyzed, only genes significantly (± ≥ 3 fold) dysregulated were shown in this table.
1
Immediate Early Response Genes; 2Late Response Genes; 3Long Term Potentiation; 4Long Term Depression; 5Cell Adhesion; 6Extracellular Matrix & Proteolytic
Processing; 7CREB Cofactors; 8Neuronal Receptors; 9Postsynaptic Density; 10Others.
If the synaptic plasticity genes expression change is ± ≥3 fold, the fold change was represented in bold letters.

nicotine alone treated SK-N-MC cells compared to the
control cells (Figure 9).

Discussion
Nicotine is the single tobacco constituent demonstrated
to have the potential to stimulate the production of
HIV-1, as has been shown using in vitro-infected alveolar macrophages [13]. A growing body of evidence suggests chronic cigarette smoking alone is associated with
abnormalities in brain morphology and neurophysiology
[31,32]. Reports on effect of nicotine on HIV associated
neurocognitive disorders are scanty. We have used SKN-MC cells to study the HIV infectivity and for the

analysis of synaptic plasticity genes expression and spine
density changes as these cells have been reported to be
susceptible for the productive HIV-1 infection [33]. In
this study, with the use of neuronal cells, we have observed that the presence of nicotine have significantly
increased HIV infection which are in agreement with
the previous reports observed in other types of cells
[18,19,34]. Rock et al., reported that TGF-β1 may be involved in the effects of nicotine on enhanced HIV-1 expression in microglial cells [19]. Out of 84 synaptic
plasticity genes analyzed, in this study, we have observed
down-regulation of 28 synaptic plasticity genes (3–38
folds) and up-regulation (3–56 folds) of 8 genes in HIV
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Figure 4 Venn diagram comparing the number of downregulated synaptic plasticity genes in SK-N-MC neuronal cells
infected with HIV and/or in the presence of nicotine.

Figure 5 qPCR analysis for HDAC2 expression in SK-N-MC cells
infected with HIV and/or treated with nicotine/vorinostat
combination. SK-N-MC cells were infected with HIV and/or treated
with nicotine. On the 5th day, 1 μg of vorinostat was added to the
nicotine treated, HIV infected, HIV + nicotine treated cells. After total
7 days of HIV infection and/or treatment with nicotine, cells were
harvested; RNA was isolated from the cells using illustra triplePrep
Kit. The qPCR analysis indicated significantly increased HDAC2
expression in nicotine treated; HIV infected and in combined treatment.
Vorinostat could able to inhibit the HDAC2 up-regulation in all the
vorinostat treated test groups. (*, p ≤ 0.05; NS-Not Significant).

Page 8 of 17

infected cells. Our results indicate that HIV infection alters the expression of synaptic plasticity genes in neuronal cells which may contribute to the disrupted
synaptic plasticity.
Nicotine treated SK-N-MC cells exhibit down-regulation
in 23 synaptic plasticity genes (3–35 fold) and upregulation in 16 genes (3–75 folds). Among these genes, 20
were commonly down-regulated in both nicotine-treated
(alone) and HIV infected cells (alone). Recent studies have
shown that nicotinic mechanisms influence forms of synaptic plasticity that are thought to underlie learning and
memory [35,36]. Although nicotine is known to have neuroprotective effects, reports indicate that nicotine do not
provide any evidence of the amelioration of the learning
deficit (and slightly worsened performance during acquisition) observed in the behavioral HIV-1 transgenic (HIV1Tg) rat model [37]. In few studies with nicotine exposure,
improved attention, learning and memory processes were
reported in both experimental animals and humans
[16,17,38]. But the positive effect of nicotine on memory
and attention is still a matter of debate in case of chronic
nicotine exposure. In this study, we observed both positive
and negative regulatory effects of nicotine on synaptic plasticity genes expression in neuronal cells after 7 days of
chronic nicotine exposure.
This is the first report to study the impact of nicotine
on synaptic plasticity genes expression in HIV infected
neuronal cells. HIV infected SK-N-MC cells in the presence of nicotine display a significant reduction in total 47
synaptic plasticity genes expression (3–84 folds) and significant up-regulation in only 4 genes expression (IGF1,
NFKBIB, PPP2CA, RAB3A) (3–15 folds). All the genes
down-regulated in nicotine/HIV infection alone are also
down-regulated (few genes synergistically) in HIV infected
cells co-treated with nicotine. The fold down-regulation
ranges from 3–84 folds indicating increased neuropathogenicity in HIV infected cells treated with nicotine. Activation of immediate early transcription factors [immediate
early genes (IEGs)] leads to the transcriptional activation
of synaptic plasticity genes that presumably play an important role in the structural and functional neuronal
changes involved in mammalian LTM [39,40]. Out of 30
immediate early response genes we have analyzed, 18
genes were significantly down-regulated in HIV infected
SK-N-MC neuronal cells in the presence of nicotine, indicating transcriptional repression of other synaptic plasticity genes, therefore decreased LTM. Synaptic plasticity
gene-gene interactions/relationships were built using the
GNCPro Gene Network Central for genes significantly
down-regulated in SK-N-MC neuronal cells Infected with
HIV (Figure 10a); Nicotine treated (Figure 10b) and HIV
infected cells in the presence of nicotine (Figure 10c).
Transcription factor NF- kappa-B (NF-kB) regulates
spatial memory formation, synaptic transmission, and
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Figure 6 Western blot analysis for HDAC2 expression in SK-N-MC cells infected with HIV and/or treated with nicotine/vorinostat
combination. SK-N-MC cells were infected with HIV and/or treated with nicotine. On the 5th day, 1 μg of vorinostat was added to the nicotine
treated, HIV infected, HIV + nicotine treated cells. After total 7 days of HIV infection and/or treatment with nicotine, cells were harvested; protein
was isolated from the cells using illustra triplePrep Kit. Transfer blots were probed with anti-HDAC2 antibody followed by secondary HRP conjugated
antibody. Western blot results support the qPCR results indicating that HDAC2 up-regulation can be inhibited by vorinostat (at 1 μg conc.) in HIV and/
or nicotine treated neuronal cells. (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; NS-Not Significant).

plasticity. Inhibition of NF-κB leads to decrease in
forskolin-induced CREB phosphorylation [41]. In this
study, along with down-regulation of NF-κB1, we have
also observed up-regulation of NFKBIB that belongs to
the NF-kappa-B inhibitor family, which inhibit NF-κB1
by complexing with, and trapping it in the cytoplasm

that may further disrupt the synaptic plasticity in HIV
infected neurons in the presence of nicotine.
NCAM1 is another highly down-regulated synaptic
plasticity gene in the HIV infected neuronal cells in the
presence of nicotine. NCAM1 is a multifunction transmembrane protein expressed in both neurons and glial

Figure 7 Representative figures for scatter plot analysis of the changes in synaptic plasticity gene expression in HIV infected SK-N-MC
neuronal cells with nicotine and in combination with vorinostat. Pair wise comparison of control SK-N-MC cells (No HIV infection) and a)
HIV + Nicotine b) HIV + Nicotine + Vorinostat treated SK-N-MC cells by scatter plot analysis. Spots associated with individual human synaptic
plasticity gene were collected and converted into log10 scale. The central line indicates unchanged gene expression. The synaptic plasticity genes
with expression levels higher or lower in treated neuronal cells than control cells are expected to produce dots that deviate from the centerline.
The dots are allocated to positions that are above or below than the +3 fold or −3 fold line when the differences are greater than three folds.
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Figure 8 Synergistic decrease of spine density in HIV infected neuronal cells in the presence of nicotine. SK-N-MC cells were infected with
HIV and/or treated with nicotine for 7 days. On the 5th day of HIV infection and/or nicotine treatment, vorinostat was added to the culture.
a) Control SK-N-MC cells: High number of long spines on the dendritic length, high dendrite diameter, total dendrite area and spine area. b) Vorinostat
treated Cells: Cells with the higher number of spines on a dendrite length similar to the control cells. c) Nicotine treated cells: Loss of spine
on a dendrite length when compared to the control cells. d) Nicotine along with vorinostat: Restoration of spines on the dendrite length
e) HIV infected cells: Loss of spines on the dendrite length, decreased dendrite diameter, dendrite and spine area was observed than the
control neuronal cells. f) HIV infected cells in the presence of vorinostat: Recovery of spines on the dendrite length was observed. g) HIV
infected cells in the presence of nicotine: Synergistic loss of number of spine on a dendrite length was observed when compare to the control
or nicotine treated or HIV infected cells. h) HIV infected cells co-treated with nicotine in the presence of vorinostat: In the presence of vorinostat, spine
density was restored when compare to the HIV + nicotine treated cells. (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001; NS-Not Significant).

cells with cell recognition properties involved in cellular
migration, synaptic plasticity [42,43] and central nervous
system development [42]. In this study, expression of
NACAM1 was recovered with the use of vorinostat
treatment.
Two other highly down-regulated synaptic plasticity
genes in HIV infected neuronal cells and in combination
with nicotine are the RHEB and TIMP1. While RHEB
plays an important role in long term activity-dependent
neuronal responses [44], TIMP1 is a candidate plasticity
gene induced by seizures and by stimuli leading to long

term potentiation. Down-regulation of these two genes
may lead to the altered learning and memory.
We have also analyzed the dendritic spine density
changes in HIV infected SK-N-MC cells co-treated with
nicotine. We have got supporting results for the gene
expression studies in SK-N-MC showing the significantly
reduced spine density in the HIV infected cells cotreated with nicotine than the control, nicotine/HIV
infected cells. We have also observed significantly decreased spine density in nicotine/HIV infected neuronal
cells than the control cells indicating neurotoxicity in
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Figure 9 Pattern of eIF2α phosphorylation (Ser51) in SK-N-MC neuronal cells infected with HIV alone and together with nicotine.
SK-N-MC cells were treated with HIV/nicotine alone and in combination. After 7 days of infection and/or nicotine treatment, eIF2α
phosphorylation (at Ser51) was analyzed by western blot assay. We have observed significant eIF2α phosphorylation in HIV and HIV + nicotine
treated groups when compared with the control cells. (*, p ≤ 0.05; NS-Not Significant).

nicotine/HIV alone infected cells as well. Reduced cortical synaptic density has been reported in mild to moderate HAND patient’s autopsy samples [45]. Our study
shows that nicotine severely affects spine density during
HIV infection. This report provides evidence of increased neuropathogencity in HIV-infected neuronal
cells exposed to nicotine and shows the induced synergistic decrease in synaptic plasticity genes expression
and spine density than HIV/Nicotine alone infected
cells. Among different nicotinic mechanisms influencing
synaptic plasticity, role of overexpressed α7-nAChRs,
which play a role in neurological disorders [46] was
studied with nicotine/HIV. Chronic exposure to nicotine
was reported to cause up-regulation of α7-nAChRs [47]
and up-regulation of α7-nAChR has been reported as a

contributor to the neurotoxicity associated with HIV infection as well [48]. Another important mechanism is
the accumulation of excess glutamate in the extracellular
space as a consequence of CNS trauma, neurodegenerative diseases, infection, or deregulation of glutamate clearance results in excitotoxicity. Most acute and chronic
neuronal diseases, including HAND, have implicated this
type of bystander pathology of excitotoxicity [49]. The
presence of excess glutamate in the synaptic clefts activates glutamate gated ion channels and results in high levels
of ion influx into neuronal cells allowing the over activation
of downstream calcium ion-dependent effectors and signaling pathways, culminating in neuronal damage. Nicotine
also reported to enhance the glutamate release [50,51].
Therefore, it may be possible that HIV in combination of

Figure 10 Gene-Gene interaction network for human synaptic plasticity genes. Human synaptic plasticity gene-gene interactions/relationships
network was built using the GNCPro Gene Network Central for genes significantly down-regulated in SK-N-MC neuronal cells a) Infected with HIV;
b) Nicotine treated; c) HIV infected cells in the presence of nicotine. The interactions are determined and color-coded by down-regulation, upregulation, regulation, co-expression, chemical modification, physical interaction, predicted protein interaction, predicted TFactor regulation and other.
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nicotine may increase the excitotoxicity mediated by glutamate release.
Further, we have investigated the mechanisms attributed
for the transcriptional and translational repression of synaptic plasticity gens in HIV infected cells and in combination with nicotine. We analyzed one of the important
mechanisms, the role of HDAC2 in the transcriptional repression of synaptic plasticity genes. Histone acetylation is
an epigenetic mark in the chromatin that favors gene expression and is modulated by the balance between histone
acetyltransferase (HAT) and histone deacetylase (HDAC)
enzyme activities, which add and remove, respectively,
acetyl groups from histones. With the use of SKNMC, we
showed significant up-regulation of HDAC2 in all the
three study groups (1. HIV infected; 2. Nicotine treated; 3.
HIV infected and co-treated with nicotine) indicating the
possible role of HDAC2 in the transcriptional repression
of synaptic plasticity genes in neurons. The evidence for
HDAC2 in the negative regulation of memory and synaptic plasticity has been well documented [26,52] and the
HDAC inhibitors especially class-I were reported as
cognitive enhancers [53,54]. Loss of HDAC2 has been
reported to improve the associative working memory
and accelerated extinction learning [52]. Recently, Hanson
et al., reported enhanced excitatory and reduced inhibitory
synaptic transmission in HDAC2 knockdown single
pyramidal neurons, whereas reduced excitatory and
enhanced inhibitory synaptic transmission in HDAC2
overexpressed neurons [55]. Earlier, from our lab, we
have reported the up-regulation of HDAC2 in human
neurons in response to the HIV-1 Tat protein induced
neurotoxicity [56]. Janus kinase (JAK)/signal transducer
and activator of transcription (STAT) pathway is known
to regulate the transcription of many genes [57-59]. Recently, the role of JAK/STAT pathway in synaptic plasticity has been reported [60].
Further we have used vorinostat, a potent, reversible
HDAC inhibitor (both Class I and Class II) to inhibit
HDAC2 expression in SK-N-MC cells infected with HIV
and/or treated with nicotine. Interestingly, we observed
increased HIV infection (latency disruption) in neuronal
cells when treated with vorinostat at 1 μM concentration
(no significant change in HIV infection in combined
treatment with nicotine and vorinostat). Vorinostat reported to disrupt the HIV latency in resting CD4+ cells
in vitro [61,62] and in vivo as well [63]. Our results suggest that vorinostat can disrupt the HIV latency in HIV
infected CNS cells as well. Therefore, reactivation of latent HIV in the neuronal cells (by using vorinostat)
along with antiretrovirals may provide a precise approach to treat and eradicate latent HIV infection in the
brain. Vorinostat could also able to inhibit the HDAC2
up-regulation in neuronal cells infected with HIV and/or
treated with nicotine. This results in a more relaxed

Page 12 of 17

chromatin configuration that allows the transcription of
synaptic plasticity genes. Figure 1 shows the schematic
representation of role of vorinostat in recovery of synaptic plasticity genes expression in neuronal cells infected
with HIV and/or treated with nicotine. We have found
that in all the groups (Nicotine, HIV infected, HIV +
Nicotine), synaptic plasticity genes expression and spine
density were recovered and many synaptic plasticity
genes were further up-regulated when treated with vorinostat compared to the control cells. In vorinostat alone
treated cells, 19 synaptic plasticity genes were significantly up-regulated and 4 genes (CREM, NFKB1, RHEB,
TIMP1) were significantly down-regulated than control
cells. Effect of down-regulation of these 4 genes in synaptic plasticity needs to be further evaluated. These results
indicate that vorinostat positively regulate synaptic plasticity genes expression and spine density in HIV infected
neurons and may be useful as a therapeutic agent in the
treatment of HAND. Zolinza (Merck, Whitehouse Station,
NJ), a prescription drug contains vorinostat is currently
being used for the treatment of cutaneous T-cell lymphoma [64], multiple myeloma [65], mesothelioma [66].
Therefore, further studies to use vorinostat as a therapeutic agent against HAND and in nicotine users need to
be studied.
In the down-stream, we have also analyzed one of the
important mechanisms i.e. eukaryotic initiation factor 2α
phosphorylation (at Ser51), which is responsible for the
translational repression of synaptic plasticity genes. Due
to partial phosphoryation of eIF2α, general translation is
reduced, and ATF4 mRNA translation is augmented. As
a consequence, expression of synaptic plasticity and
memory-related genes is depressed (Figure 2). Decreased
eIF2α phosphorylation reduces ATF4 mRNA translation
and enhances general mRNA translation, thus facilitating
the induction of synaptic plasticity genes expression,
which leads to L-LTP and long-term memory (LTM) consolidation [67]. In our study, we have found increased
eIF2α phosphorylation in two-study group of neurons
(1. HIV infected; and 2. HIV infected and co-treated
with nicotine). It is indicating that translation of synaptic plasticity genes will also be effected in the neuronal
cells infected with HIV and in combined treatment with
nicotine. To the best of our knowledge, till now, there
are no reports of translational repression in HIV infected cells mediated by eIF2α phosphorylation. Therefore, further regulation of eIF2α phosphorylation in
HIV infected neurons should be studied to control the
translation of synaptic plasticity genes.

Conclusions
There are few reports showing the cognitive impairment
in heavy smokers [68-71]. Effects of cigarette smoking
on cognitive disorders in HIV infected patients are
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scanty [23,72]. This is the first study in analyzing the molecular mechanisms behind the increased risk of HAND in HIV
infected nicotine users. This study concludes that HIV infected nicotine users are more prone to develop HAND
symptoms compared to HIV infected patients who are not
nicotine addicts, due to the HDAC2 induced transcriptional
repression. These negative regulatory effects on synaptic plasticity genes expression and spine density may be reversed by
using the vorinostat (class I and II HDACs inhibitor). Vorinostat may be a useful therapeutic to inhibit the neurotoxic effects on synaptic plasticity in HIV infected nicotine abusers.

Materials and methods
Cell culture and virus

SK-N-MC neuronal cells were obtained from ATCC
(Cat # HTB-10). HIV-1Ba-L (clade B, macrophage-tropic
[R5] virus) was obtained through AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH (NIH AIDS Reagent Program Cat. # 510).
HIV-1 infection and/or nicotine treatment of
SK-N-MC cells

SK-N-MC neuronal cells were infected with HIV-1 using
the previously described protocol [13,73-75] with slight
modifications. Briefly, SK-N-MC cells (1×106 cells) were
cultured overnight in T-75 flasks using complete minimum essential medium. The cells were activated by
treating with polybrene (10 μg/ml) for 8 hrs before the
infection. The cells were infected with TCID50 of HIV-1
and/or treated with 1 μM-1 mM nicotine (Sigma, Cat #
N3876) for 7–10 days under same experimental conditions. In every second day, 2 ml of fresh medium (with/
without nicotine) was added to the culture. Controls
cells (without HIV-1/Nicotine) were included in the setup of all experiments.
Inhibition of HDAC2 up-regulation

SK-N-MC cells were infected with HIV and/or treated
with nicotine as explained above. On the 5th day of HIV
infection and/or nicotine treatment, SK-N-MC cells
were treated with 0.1-10 μM vorinostat. After total 7 days
of HIV infection and/or nicotine treatment, expression
of HDAC2 was analyzed by qPCR and western blot.
mRNA and protein extraction; and first strand cDNA
synthesis

After 7 days of HIV infection and/or co-treatment with
optimum concentration of nicotine (100 μM)/Vorinostat
(1 μM), SK-N-MC cells were harvested and the pellet
was used for the mRNA isolation using illustra triplePrep Kit (GE Healthcare Life Sciences, UK; Cat # 289425-44) and on-column DNase treatment step was also
performed in the procedure. Purity and concentration of
the RNA was measured by microspot RNA reader
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(Synergy HT Multi-Mode Microplate Reader from BioTek, US) and RNAs with an OD260 nm/OD280 nm absorbance ratio of at least 2.0 were used for PCR array.
This mRNA was also used for the long terminal repeat
(LTR) and HDAC2 gene expression using RT-qPCR.
One microgram of RNA from all the control and test
groups (1. Uninfected/untreated; 2. Nicotine; 3. HIV; 4.
HIV + Nocotine; 5. Vorinostat; 6. Nicotine + Vorinostat; 7.
HIV + Vorinostat and 8. HIV + Nicotine + Vorinostat) was
used for the first strand cDNA synthesis using SABiosciences’s RT2 First Strand Kit (Cat. # 330401) as per supplier’s protocol. Genomic DNA elimination step was
performed prior to reverse transcription. With the use of
illustra triplePrep Kit, from the same set of samples, protein was precipitated and preceded for SDS-PAGE after
the estimation of protein concentration.
QPCR of viral transcripts in the presence of nicotine

The cDNA for m-RNA isolated from all control and test
groups (as mentioned above) was synthesized using the
high-capacity reverse transcriptase cDNA kit (Applied
Biosystems, Cat # 4368814) to perform qRT-PCR by Taqman gene expression assay as described by manufacturer’s
protocols. A quantitative HIV-1 DNA protocol (LTR realtime PCR) was used to analyze the viral transcripts in HIV
infected SK-N-MC cells and in combination with nicotine
and vorinostat. The following previously published [76]
primers and probes were used: LTR U5/R-sense-5′-GG
CTAACTAGGGAACCCACTG-3′ and antisense-5′-CTG
CTAGAGATTTTCCACACTGAC-3′, probe 5′-FAM-TG
TGTGCCCGTCTGTTGTGTG-TAMRA-3′. Values were
normalized against GAPDH.
Expression of HDAC2 in SK-N-MC neuronal cells infected with
HIV and/or treated with nicotine/vorinostat combination

In the SK-N-MC cells infected with HIV and/or treated
with nicotine/vorinostat combination (as explained above),
expression levels of HDAC2 was measured by qPCR with
the use of Taqman assay (Assay ID # Hs00231032_m1)
and by western blot using anti-HDAC2 antibody (Millipore
cat # 07–222).
Human synaptic plasticity RT2 profile PCR array

Synaptic plasticity gene expression profiling was done in
all the neuronal cell control and test groups (all the groups
as mentioned above) using 96 well format RT2 Profile
PCR Array human Synaptic Plasticity kit (SABiosciences,
Cat. # PAHS-126A-2) using Stratagene Mx3000p qRTPCR instrument. The human Synaptic Plasticity RT2
Profiler PCR Array interrogates 84 genes related to the
human synaptic plasticity. This kit was chosen because it
includes diverse genes important in the human synaptic
plasticity, including Immediate-Early Response (n = 30),
Late Response (n = 2), Long Term Potentiation (n = 28),
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Long Term Depression (n = 21), Cell Adhesion (n = 9),
Extracellular Matrix & Proteolytic Processing (n = 5),
CREB Cofactors (n = 10), Neuronal Receptors (n = 19),
Postsynaptic Density (n = 15), as well as other genes involved in the synaptic plasticity (n = 2). Few genes have
role in multiple functions listed above. Relative abundance of each mRNA species was assessed using RT2
SYBR Green/ROX PCR Master mix (SABiosciences, Cat #
330520) and aliquoted in equal volumes (25 μl) to each
well of the real-time PCR arrays. The real-time PCR cycling program (as indicated by the manufacturer) was run
on a Stratagene Mx3000p qRT-PCR thermal cycler. The
threshold cycle (Ct) of each gene was determined by
using the Stratagene MaxPro software. CT data were
uploaded into the data analysis template on the manufacturer's website (http://pcrdataanalysis.sabiosciences.
com/pcr/arrayanalysis.php). The relative expression of
each gene in each test group was compared with the
expression in control cells and it was calculated on the
website using the ΔΔCT method with five housekeeping
genes as controls. Controls are also included on each array
for genomic DNA contamination, RNA quality, and general
PCR performance.
Measurement of spine density
DiI staining

Established protocol to stain the neuronal cells and measurement of the spine density (in all the control and test
group neuronal cells) was used with few modifications
[13,74,77-81]. In brief, SK-N-MC cells were grown in
Eagle’s minimal essential medium (MEM) containing 10%
fetal bovine serum (FBS), 5 mM sodium pyruvate, 100
units/ml penicillin, 100 mg/ml streptomycin and retinoic
acid at 37°C with 5% CO2. SK-N-MC cells were grown
onto 22 mm × 50 mm glass coverslips placed in a petridish. Cells were treated with polybrene for 8 hrs followed
by addition of HIV and/or nicotine. On the 5th day of HIV
infection and/or nicotine treatment, vorinostat (1 μM) was
added to the respective test groups. After 7 days of infection
and/or treatment with nicotine, cells were fixed in 4% Formaldehyde in PBS for 30 min at RT. The fluorescent membrane
tracer 1, 1'-Dioctadecyl-3, 3,3’,3’-tetramethylindocarbocyanine
perchlorate (DiI) at 5 μg/ml in PBS concentration was directly
added onto the fixed cultures and allowed to incubate for
90 min at RT. The stained coverslips were placed at 4˚C in
small petri dishes containing PBS and allowed for overnight
for the transport of dye. Cover-slips were mounted on the
slides with Prolong®Gold antifade reagent (Invitrogen) before
proceeding for confocal microscopy.
Confocal microscopy

Confocal images were obtained using TCS SP2 Confocal
Laser Scanning Microscope (Leica Microsystems, Germany)
at 488 nm (100%) illusion of an argon-ion laser using 60X
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oil immersion objectives with high numeric aperture and
2.5X confocal electronic zoom settings to visualize individual cells and dendrites. Twenty Optical serial sections of
0.14 μm/section (~2.8 μm total) through the cells were reconstructed to yield complete “two dimensional” images of
individual cells in focus.
Western blot assay

For SDS-PAGE, similar amounts of control and test
group SK-N-MC cellular protein, typically 40 μg per lane
were used. All the protein samples were separated by
using Any KD Mini-Protean TGX precast Gels (Bio-Rad,
Cat # 456–9034). Proteins were transferred to nitrocellulose membranes, and the quality of protein measurement, electrophoresis, and transfer was checked by
staining with Ponceau S. Membranes were blocked with
5% skimmed milk in TBS-T (20 mM Tris buffer, pH 7.5,
0.5 M NaCl, 0.1% Tween 20) for 1 hr at room
temperature and incubated at 4°C overnight in the primary antibody diluted in 2% skimmed milk in TBS-T.
The primary antibodies used were as follows: antiHDAC2 antibody (Millipore cat # 07–222, 1/5000);
rabbit anti-phospho-eIF2α (Ser51) antibody (Cat # 9721,
1/1000), rabbit anti-eIF2α antibody (Cat # 9722, 1/1000)
from Cell Signaling (Beverly, MA). Subsequently, blots
were washed in TBS-T (4 times, 10 min each) and incubated for 1 hr at room temperature in horse radish
peroxidase-goat anti-rabbit antibody (Promega, Cat #
W401B) diluted 1/2500 in 2% skim milk in TBS-T. After
additional washings, protein bands were detected by chemiluminiscence using SuperSignal West Pico Luminol/Enhancer (Thermo Scientific, Cat # 1856136) and SuperSignal
West Pico substrate (Thermo Scientific, Cat # 1856135).
Band density was measured by using ImageJ software.
Data analysis

In the expression studies, a gene was considered differentially regulated if the difference was ≥3 fold in comparison with the control. Experiments were performed
at least three times and the values obtained were averaged. All the results are expressed as mean ± standard
error of the mean. Statistical analysis of two groups was
performed by Student’s t test, while more than two
groups were analyzed using one way ANOVA followed
by Bonferroni’s multiple comparison test. Differences
were considered significant at p ≤ 0.05. If the combined
effect observed is significantly greater than the expected
(additive) effect, it was considered synergism [82]. Data
analysis was performed with the Statistical Program,
GraphPad Prism software (La Jolla, CA).
ImageJ software program was used to quantify DiIlabeled cells. Dendritic segments were chosen randomly
from the apical and basal regions and at least one soma’s
length away from the cell soma.
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